The Glaucoma Drugs Market: 2021 – 2030 – Opportunities, Challenges, Strategies & Forecasts

Release Date: October 2021
Number of Pages: 231
Number of Tables and Figures: 47
Clinical Pipeline Candidates: 55

Synopsis: Often cited as the leading cause of irreversible blindness worldwide, glaucoma is a complex eye disease in which damage to the optic nerve leads to progressive, permanent vision loss. Although this damage is usually caused by increased IOP (Intraocular Pressure) inside the eye, even patients with normal range IOP can develop glaucoma.

Glaucoma can be treated with eye drops, injections, oral pills, laser treatment or surgery. Expected to surpass $10 Billion in global spending by the end of 2021, drugs remain the preferred approach to treat most cases of glaucoma.

The market is ripe for growth with three approvals over the last few years, and a number of novel therapies in late-stage development.  The glaucoma pipeline also includes fixed dose combinations (FCs), which have the potential for improving patient adherence while decreasing exposure of preservatives to the eye.
The “Glaucoma Drugs Market: 2021 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the glaucoma drugs ecosystem including treatment options, delivery technologies, key trends, market drivers, challenges, investment potential, leading therapies, drug development pipeline, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for glaucoma drugs from 2021 through to 2030. The forecasts are segmented for 6 drug classes, 5 regions and 25 leading countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report and the Glaucoma drug development pipeline data.
For a Sample and Table of Contents please contact info@snsintel.com

Pricing: The report is available for the following price: 

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500

Key Findings:
The report has the following key findings:
  • Expected to surpass $10 Billion in global spending by the end of 2021, drugs remain the preferred approach to treat most cases of glaucoma. As new drugs continue to revitalize glaucoma treatment options, the market is expected to continue its upward trajectory beyond 2021.
  • Approvals of AbbVie’s dissolvable implant of the prostaglandin analog Durysta (bimatoprost) and  Sun Pharma’s branded drug without benzalkonium chloride (BAK) preservative Xelpros (lantanoprost), are showing promising results in glaucoma treatment, particularly for patients whose needs were not being met with existing therapies.
  • New advancements in neuroprotection could preserve the optic nerve with treatments to block primary destructive events in retinal ganglion cells (RGCs), altering the process and progression of the disease. 
  • A number of new classes of drugs – ranging from therapeutic proteins and gene & cell therapies to cannabinoids and Tie2 pathway activators –  are being evaluated as part of pre-clinical and early-stage development programs.
  • Several novel approaches to glaucoma drug delivery are beginning to emerge, such as biodegradable implants for the sustained release of IOP-lowering medication over a period of months, and precise micro-dosing technologies to alleviate the inefficiencies associated with the high doses delivered by conventional eye droppers.

Topics Covered:
The report covers the following topics:
  • Glaucoma drugs ecosystem
  • Market drivers and barriers
  • Review of glaucoma and related conditions
  • Role of drugs in glaucoma and key trends
  • Analysis of key drug classes and leading glaucoma therapies
  • Drug development pipeline for glaucoma
  • Advanced drug delivery technologies
  • Future Industry roadmap and value chain
  • Profiles and strategies of over 90 leading ecosystem players, including glaucoma drug developers
  • Strategic recommendations for ecosystem players
  • Market analysis and forecasts from 2021 till 2030

Historical Revenue & Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Drug Classes
    • Prostaglandin Analogs
    • Beta Blockers
    • Alpha Agonists
    • Carbonic Anhydrase Inhibitors
    • Combinations & Others
  • Regional Markets
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America
  • Country Markets
    • Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Africa
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the glaucoma drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2021 and at what rate will it grow?
  • Which countries and submarkets will see the highest percentage of growth?
  • What are the prospects of biodegradable ocular implants and other advanced drug delivery technologies?
  • How big is the market for combination formulations, and new drug classes such as ROCK (Rho Kinase) inhibitors?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of innovator drugs impact the market?
  • What strategies should glaucoma drug developers adopt to remain competitive?

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:

AbbVie
AC Immune
Acorn Biomedical
Aerie Pharmaceuticals
Aerpio Pharmaceuticals
Akorn Pharmaceuticals
Alcon
Allysta Pharmaceuticals
Altacor
Amarantus Bioscience Holdings
Amgen
Amorphex Therapeutics
Annexon Biosciences
Astellas Pharma
Bausch Health Companies Inc.
Bayer
Betaliq
BetterLife Pharma Inc.
Bial
BioAxone Biosciences
BioLight Life Sciences
Bionure Farma
Can-Fite BioPharma
Chong Kun Dang Pharmaceutical Corporation
Clearside Biomedical
Colby Pharmaceutical Company
D.Western Therapeutics Institute
DHP KOREA
Dompé Farmaceutici
Elsalys Biotech (Mediolanum Farmaceutici Spa group)
Envisia Therapeutics
Euclid Systems Corporation
Eyenovia
EyePoint Pharmaceuticals
EyeRx Research
Eyevensys
Fera Pharmaceuticals
Gene Signal
Glaukos Corporation
Graybug Vision
Handok
HitGen
iCo Therapeutics
ID Pharma Co.
InMed Pharmaceuticals
Inotek Pharmaceuticals
InSite Vision
Isarna Therapeutics
Kowa Company
Laboratorios SALVAT
Laboratorios Sophia
Lee's Pharmaceutical Holdings
Lexicon Pharmaceuticals
Mallinckrodt
MANF Therapeutics
Mannin Research
Mati Therapeutics
MediPrint Ophthalmics
Merck & Co.
MimeTech
Mundipharma International
Nanogenics
NEMUS Bioscience
NeuBase Therapeutics
Neuregenix
Neurim Pharmaceuticals
Neurotech Pharmaceuticals
Nicox
NoNo
Novaliq
Novartis
Ocular Therapeutix
Oculis Pharma
Oncolys BioPharma
ONO Pharmaceutical
Otero Therapeutics
Otsuka Holdings Company
Otsuka Pharmaceutical
Peregrine Ophthalmic
Perrigo Company
Pfizer
pH Pharma
PharmaMar
PolyActiva
Procter & Gamble
Q BioMed
Qlaris Bio
Quark Pharmaceuticals
Quethera
Radikal Therapeutics
Recordati
Regeneron Pharmaceuticals
Replenish
Roche Holding (F. Hoffmann-La Roche)
Rocket Pharmaceuticals
Salvat
Santen Pharmaceutical Company
Satellos Bioscience
Senju Pharmaceutical Company
SPARC (Sun Pharma Advanced Research Company)
Sun Pharma (Sun Pharmaceutical Industries)
Sylentis
Taejoon Pharm
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
THÉA Laboratories
TikoMed
U.S. FDA (Food and Drug Administration)
Ube Industries
ViSci subsidiaries
Wakamoto Company
Wize Pharma
XLVision Sciences